ERCC2 and carcinoma: In particular, our results demonstrated a substantial reduction in the transcript levels of ERCC1 and XPD in all MPM cell lines, as previously detected in a cisplatin-resistant carcinoma cell line treated with 5-FU, as well as in colorectal cancer cell lines treated with pemetrexed (Fujishima et al, 1997; Nannizzi et al, 2010).